الفهرس 
Introduction.Only 14 pages are availabe for public view
 |  | from | 78 |  |  |
| | | from | 78 | | |
Abstract
Retinal vein occlusion is one of the vascular disorders affecting
vision. Branch retinal vein occlusion is three times more common than
central retinal vein occlusion and is second only to diabetic
retinopathy as the most common retinal vascular cause of visual
impairment .There are many lines of treatment to macular edema
secondary to RVO. One of them is intravitreal injection of antiedematous
substances such as Triamcinolone acetonide and Anti-
VEGF. This study compared the effect of intravitreal injection of
Triamcinolone acetonide , Bevacizumabe and combination of both for
the treatment of macular edema secondary to retinal vein occlusion.
The included patients in this study undergone full ophthalmological
examination as Best corrected visual acuity measurement using
snellen eye chart, Anterior segment examination using slit lamp ,
Intraocular pressure using Goldmann applanation tonometer, Posterior
segment examination after pupillary dilatation using Slit lamp
biomicroscopy with +90 and +78 diopter volk lens, Fundas
flourescein angiography was done using Canon fundus camera and
Optical coherence Tomography (OCT) to assess the central foveal
thickness was done using Heidelberg Optical coherence tomograsphy .
Then the selected patients were divided randomly into three groups :
Group 1: Included 20 eyes of 19 patients with retinal vein
occlusion (9 BRVO,11 CRVO) received intravitreal
bevacizumab injection (IVB) 2.5 mg/0.1ml.
Group 2: Included 18 eyes of 18 patients with retinal vein
occlusion (10 BRVO,8 CRVO) received intravitreal
triamcinolone acetonide injection (IVT) 4mg/ 0.1ml.
Summary
58
Group 3: Included 17 eyes of 17patients with retinal vein
occlusion (9 BRVO,8 CRVO) received combined intravitreal
injection of bevacizumab (Avastin) (IVB) 1.25 mg/0.05ml and
triamcinolone acetonide (IVT) 2mg/0.1ml ( combined ).
The patients were examined at 1,3,6 months for follow up and
showed that all the three kinds of treatment resulted in significant
reduction of central macular thickness throughout six months.
Compared to baseline, visual acuity was significantly better in all
three groups at 1,3 and 6 months. Bevacizumab monotherapy and
combined groups maintained better visual acuity while the
triamcinolone group did not at three and six months.
At six months, only bevacizumab injected eyes showed highly
significant improvement in visual acuity.
The bevacizumab group showed the higher rate of re-injections
but least complications compared to the other groups.